Daniel R Mazori1, Alisa N Femia2, Ruth Ann Vleugels3. 1. Department of Dermatology, State University of New York Downstate Medical Center, Brooklyn, NY, USA. 2. The Ronald O. Perelman Department of Dermatology, New York University Langone Medical Center, New York, NY, USA. 3. Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA. rvleugels@partners.org.
Abstract
PURPOSE OF REVIEW: First recognized in 1974, eosinophilic fasciitis (EF) is a fibrosing disorder of the fascia with characteristic cutaneous and hematologic manifestations. This review discusses recent trends in the diagnosis and treatment of EF. RECENT FINDINGS: Although fascial biopsy has classically been considered the gold standard for making a diagnosis of EF, radiologic imaging, particularly magnetic resonance imaging, has been increasingly used for both diagnosis and monitoring of treatment response. Systemic corticosteroids remain the first-line treatment for EF; however, their often prolonged use in the treatment of EF has prompted a search for adjunctive therapies. Methotrexate has emerged as the leading corticosteroid-sparing agent for EF. Since EF was initially described over 40 years ago, important diagnostic and therapeutic progress has been made. Future efforts should be directed at the pursuit of prospective studies including clinical trials and evidence-based guidelines.
PURPOSE OF REVIEW: First recognized in 1974, eosinophilic fasciitis (EF) is a fibrosing disorder of the fascia with characteristic cutaneous and hematologic manifestations. This review discusses recent trends in the diagnosis and treatment of EF. RECENT FINDINGS: Although fascial biopsy has classically been considered the gold standard for making a diagnosis of EF, radiologic imaging, particularly magnetic resonance imaging, has been increasingly used for both diagnosis and monitoring of treatment response. Systemic corticosteroids remain the first-line treatment for EF; however, their often prolonged use in the treatment of EF has prompted a search for adjunctive therapies. Methotrexate has emerged as the leading corticosteroid-sparing agent for EF. Since EF was initially described over 40 years ago, important diagnostic and therapeutic progress has been made. Future efforts should be directed at the pursuit of prospective studies including clinical trials and evidence-based guidelines.
Authors: Leticia Alonso-Castro; Elena de las Heras; Carmen Moreno; Beatriz Fleta-Asín; Ernesto Muñoz-Zato; Rosario Carrillo; Pedro Jaén Journal: Int J Dermatol Date: 2014-04-02 Impact factor: 2.736
Authors: L Frumholtz; M Sebert; A de Masson; P Attias; L Ades; J Roux; M Jachiet; A Cabannes-Hamy; M Elena Noguera; C Attencourt; M Bagot; G Socié; M Rybojad; R Peffault de La Tour; J D Bouaziz Journal: J Eur Acad Dermatol Venereol Date: 2016-07-12 Impact factor: 6.166
Authors: T Kirchgesner; B Dallaudière; P Omoumi; J Malghem; B Vande Berg; F Lecouvet; F Houssiau; C Galant; A Larbi Journal: Diagn Interv Imaging Date: 2015-03-04 Impact factor: 4.026
Authors: Eugene Y Kissin; Amit Garg; Peter C Grayson; Maureen Dubreuil; Diana Vradii; Michael York; Robert W Simms Journal: J Clin Rheumatol Date: 2013-10 Impact factor: 3.517
Authors: Elizabeth Tkachenko; Alexa B Steuer; Kelly Lo; Avery LaChance; Joseph F Merola; Alisa N Femia; Ruth Ann Vleugels Journal: JAMA Dermatol Date: 2020-05-01 Impact factor: 10.282
Authors: Maria Ester Simeira Fonseca; Maria Victória Quaresma; Ana Paula Luppino-Assad; Henrique Carriço da Silva; Danieli Castro O Andrade; Percival D Sampaio-Barros Journal: Rheumatol Int Date: 2017-12-15 Impact factor: 2.631
Authors: Karmela Kim Chan; Cynthia Magro; Alexander Shoushtari; Charles Rudin; Veronica Rotemberg; Anthony Rossi; Cecilia Lezcano; John Carrino; David Fernandez; Michael A Postow; Arlyn Apollo; Mario E Lacouture; Anne R Bass Journal: Oncologist Date: 2019-10-15